Roche Holding AG (RHHBF)
OTCMKTS
· Delayed Price · Currency is USD
347.30
0.00 (0.00%)
Apr 17, 2025, 4:00 PM EDT
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
$666,883
Profits / Employee
$88,465
Market Cap
250.02B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 103,249 | -356 | -0.34% |
Dec 31, 2023 | 103,605 | -8 | -0.01% |
Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
Dec 31, 2021 | 100,920 | -545 | -0.54% |
Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 3,116 |
Elite Pharmaceuticals | 64 |
Glass House Brands | 374 |
Northwest Biotherapeutics | 25 |
CytoDyn | 9 |
American Oncology Network | 1,914 |
Longduoduo Company | 49 |
Roche Holding AG News
- 3 days ago - Oak Hill Bio Enters into Exclusive License Agreement with Roche to Obtain Global Rights for a Phase 3-Ready, Potential Best-in-Class Treatment for Individuals with Angelman Syndrome - Business Wire
- 4 days ago - European Commission approves Roche's Columvi as the first bispecific antibody for diffuse large ... - GuruFocus
- 4 days ago - European Commission approves Roche's Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy - GlobeNewsWire
- 7 days ago - Roche: Forget Tariffs And Focus On The Positives -- There Are Many - Seeking Alpha
- 7 days ago - Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight - Benzinga
- 7 days ago - Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages - CNBC
- 7 days ago - Zealand Pharma Goes on Hiring Spree as It Gears Up for Obesity Tie-Up With Roche - WSJ
- 7 days ago - Biocon shares rise over 3% as USFDA approves bevacizumab biosimilar Jobevne™ for cancer treatment - Business Upturn